Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.35 |
| ▸ | DPP4 | P27487 | 9/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1155138 | 1.00 | ATM (0.50) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL3397495 | 1.00 | ATM (0.50) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL5644039 | 1.00 | ATM (0.50) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL21105707 | 0.85 | ATM (0.47) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL29489487 | 0.85 | ATM (0.47) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL3524882 | 0.83 | ATM (0.70) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL19859070 | 0.83 | ATM (0.70) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL1249538 | 0.83 | ATM (0.70) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL2744860 | 0.83 | ATM (0.70) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL4278865 | 0.83 | ATM (0.70) | ATMPIK3CDDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661922-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Dyax Corp. (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019028362-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2019-02-07 | — | — | WO | disclosed |
| US-8304411-B2 | Dicycloazaalkane derivates, preparation processes and medical uses thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2012-11-06 | — | — | US | disclosed |
| US-20100311747-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311747-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | DPP4, DPP8, DPP7 | ATM 3104/4885PIK3CD 649/4885DPP4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.